Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Quality of Life in Patients Undergoing Double Umbilical Cord Blood Vs. Haploidentical Marrow Transplantation: A QOL Analysis Report of BMT CTN 1101

Najla El Jurdi, Michael Martens, Claudio G. Brunstein, Paul O'Donnell, Stephanie J. Lee, Anita D'Souza, Brent Logan, Sanghee Hong, Karam Sandhu, Roman M Shapiro, Anurag K. Singh, Mary M. Horowitz, Betty K. Hamilton

Blood (2022) 140 (Supplement 1): 10545–10546.

https://doi.org/10.1182/blood-2022-158828

Published: 2022

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment

Johnnie J. Orozco, Aimee Kenoyer, Ethan R. Balkin, Ted A. Gooley, Donald K. Hamlin, D. Scott Wilbur, Mark D. Hylarides, Sofia H. L. Frost, Raya Mawad, Paul O’Donnell, Brenda M. Sandmaier, Ephraim J. Fuchs, Leo Luznik, Damian J. Green, Ajay K. Gopal, Oliver W. Press, John M. Pagel

Blood (2016) 127 (3): 352–359.

https://doi.org/10.1182/blood-2014-12-617019

Published: 2016

Includes: Supplemental data

Journal Articles

Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients

Monica S Thakar, MD, Mark C. Walters, MD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Mary E. D. Flowers, MD, H. Joachim Deeg, MD, Paul O'Donnell, MD, PhD, Ann E. Woolfrey, MD, Hans-Peter Kiem, MD

Blood (2013) 122 (21): 4561.

https://doi.org/10.1182/blood.V122.21.4561.4561

Published: 2013

Journal Articles

Post-Transplantation Cyclophosphamide Following Busulfan and Fludarabine Myeloablative Conditioning Prevents Severe Acute and Chronic Graft-Versus-Host Disease and Minimizes Duration Of Immunosuppression: Results Of a Multi-Institutional Trial In Patients With High-Risk Hematologic Malignancies

Christopher G. Kanakry, MD, Paul O’Donnell, MD, PhD, Terry Furlong, NP, Marcos J de Lima, MD, Wei Wei, MS, Marta Medeot, MD, Marco Mielcarek, MD, Richard E Champlin, MD, Richard J. Jones, Peter F. Thall, PhD, Borje S. Andersson, MD, PhD, Leo Luznik

Blood (2013) 122 (21): 3310.

https://doi.org/10.1182/blood.V122.21.3310.3310

Published: 2013

Journal Articles

Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignancies Is Comparable to Unrelated Donor Transplantation: A Retrospective Single-Center Study

Filippo Milano, MD, PhD, Theodore A. Gooley, PhD, Paul O'Donnell, MD, PhD, Boglarka Gyurkocza, M.D., H. Joachim Deeg, MD, Anne Woolfrey, MD, Frederick R. Appelbaum, MD, Colleen Delaney, MD, MSc

Blood (2012) 120 (21): 1995.

https://doi.org/10.1182/blood.V120.21.1995.1995

Published: 2012

Journal Articles

Anti-CD45 Radioimmunotherapy Facilitates Donor Engraftment and Prolongs Survival in the Absence of TBI Prior to Haploidentical Bone Marrow Transplantation in a Disseminated Murine Leukemia Model

Johnnie J. Orozco, MD, PhD, Aimee Kenoyer, BS, Ethan R. Balkin, PhD, Donald K. Hamlin, BS, D Scott Wilbur, PhD, Darrell R. Fisher, PhD, Shani L. Frayo, BS, Mark D. Hylarides, PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Paul O'Donnell, MD, PhD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 4101.

https://doi.org/10.1182/blood.V120.21.4101.4101

Published: 2012

Journal Articles

Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT

Raya Mawad, MD, Paul O'Donnell, MD, PhD, Ted A. Gooley, PhD, Joseph G Rajendran, MD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, H. Joachim Deeg, MD, Andrew Shields, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 4164.

https://doi.org/10.1182/blood.V120.21.4164.4164

Published: 2012

Journal Articles

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Robert W. Chen, MD, Stephen J. Forman, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Leslie Popplewell, MD, Maria L Delioukina, MD, Torres Alejandra, MS, Bernadette Pulone, RN, OCN, Eileen P. Smith, MD, Auayporn P. Nademanee, MD, Chatchada Karanes, MD, Paul O'Donnell, MD, PhD, David G. Maloney, MD, PhD, Len Farol, MD, Schickwann Tsai, MD, PhD, Laurie E. Grove, PA-C, Ajay K. Gopal, MD

Blood (2011) 118 (21): 664.

https://doi.org/10.1182/blood.V118.21.664.664

Published: 2011

Journal Articles

Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.

Ravinder Sandhu, MD, Stephen Petersdorf, MD, Brenda M. Sandmaier, MD, Paul O'Donnell, MD, PhD, Pamela S. Becker, MD, PhD, H. Joachim Deeg, MD, Frederick R Appelbaum, MD, Elihu H. Estey, MD

Blood (2009) 114 (22): 4332.

https://doi.org/10.1182/blood.V114.22.4332.4332

Published: 2009

Journal Articles

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Blood (2007) 110 (11): 173.

https://doi.org/10.1182/blood.V110.11.173.173

Published: 2007

Journal Articles

Myeloablative Allogeneic Bone Marrow Transplantation (AlloBMT) with T Cell Depletion (TCD) and Post-Transplant GM-CSF for Patients with High Risk MDS.

Erica Warlick, MD, Richard J. Jones, MD, Elizabeth Garrett-Mayer, PhD, Paul O’Donnell, MD, PhD, B. Douglas Smith, MD

Blood (2006) 108 (11): 5309.

https://doi.org/10.1182/blood.V108.11.5309.5309

Published: 2006

Journal Articles

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Paul O’Donnell, MD, PhD, Leo Luznik, MD, Heather Symons, MD, Richard Jones, MD, Ted Gooley, PhD, Elizabeth Harrington, MSN, Sandra Warnock, Brenda Sandmaier, MD, Rainer Storb, MD, Ephraim Fuchs, MD

Blood (2006) 108 (11): 3135.

https://doi.org/10.1182/blood.V108.11.3135.3135

Published: 2006

NARROW

Quality of Life in Patients Undergoing Double Umbilical Cord Blood Vs. Haploidentical Marrow Transplantation: A QOL Analysis Report of BMT CTN 1101

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment

Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients

Post-Transplantation Cyclophosphamide Following Busulfan and Fludarabine Myeloablative Conditioning Prevents Severe Acute and Chronic Graft-Versus-Host Disease and Minimizes Duration Of Immunosuppression: Results Of a Multi-Institutional Trial In Patients With High-Risk Hematologic Malignancies

Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignancies Is Comparable to Unrelated Donor Transplantation: A Retrospective Single-Center Study

Anti-CD45 Radioimmunotherapy Facilitates Donor Engraftment and Prolongs Survival in the Absence of TBI Prior to Haploidentical Bone Marrow Transplantation in a Disseminated Murine Leukemia Model

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma

Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy.

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Myeloablative Allogeneic Bone Marrow Transplantation (AlloBMT) with T Cell Depletion (TCD) and Post-Transplant GM-CSF for Patients with High Risk MDS.

Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only